A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples